Raymond M. Paranal

KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS

Chiara Ambrogio, Jens Köhler, Zhi-Wei Zhou et al. · Cell · 2018 · 281 citations · Full text

Oncogenic Activity, Receptor Tyrosine Kinase, Mutant Kras +3

Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C

Mei Zeng, Jia Lu, Lianbo Li et al. · Cell chemical biology · 2017 · 134 citations · Full text

Medicinal Chemistry, Kras G12c, Medicine +6

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors

Takayuki Kosaka, Junko Tanizaki, Raymond M. Paranal et al. · Cancer Research · 2017 · 129 citations · Full text

Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives

Samar Mowafy, Athanasios Galanis, Zainab M. Doctor et al. · Bioorganic & Medicinal Chemistry · 2016 · 60 citations · Full text

Medicinal Chemistry, Thioureido-quinazoline Derivatives, Mutant Egfr Inhibitors +9

Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of <i>EGFR</i> -mutant lung cancer

Pınar Ö. Eser, Raymond M. Paranal, Jieun Son et al. · Science Translational Medicine · 2021 · 17 citations · Full text